Is Grifols (BME:GRF) A Bargain On Mixed Half Year Earnings?
Grifols (BME:GRF) has been in focus after its half year 2026 report showed sales of €3,574 million compared to €3,677 million a year earlier, while net income reached €227 million against €177 million.
See our latest analysis for Grifols.
The recent half year 2026 report appears to have been the key driver behind Grifols’ 13.11% 1 month share price return and 12.41% 3 month share price return, although the total shareholder return over 1 and 5 years remains sharply lower. This suggests momentum is improving from a weak longer term base.
If you are weighing Grifols’ recent move and want more ideas in healthcare, this could be a good moment to check out 128 healthcare AI stocks
The recent swing in Grifols raises a simple question. Are investors responding to healthier profits behind softer sales, or has sentiment just moved off a low base before the valuation truly stacks up?
Most Popular Narrative: 29.1% Undervalued
Grifols last closed at €10.20 while the most followed narrative pegs fair value at about €14.40. That gap is built on a detailed set of growth and margin assumptions rather than a quick sentiment swing.
Robust global demand for plasma-derived therapies is driving above-market revenue growth for Grifols' core immunoglobulin, albumin, and alpha-1 franchises, a trend supported by increased disease prevalence from an aging population and rising diagnosis rates, which is expected to support sustained revenue expansion.
Want to see what is behind that revenue story and fair value gap? The narrative focuses on rising earnings power, firmer margins, and a higher future P/E anchor.
Result: Fair Value of €14.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Grifols story still hinges on managing high debt and avoiding disruption at its plasma collection centres. Either of these issues could quickly challenge this upbeat narrative.
Find out about the key risks to this Grifols narrative.
Next Steps
With mixed signals on Grifols so far, this is a good time to move quickly, review both sides of the story, and weigh the 4 key rewards and 2 important warning signs
Looking for more ideas beyond Grifols?
If Grifols has sharpened your interest, do not stop here. Spend a few focused minutes with the Simply Wall St Screener so you do not miss other compelling setups.
- Target potential value opportunities by reviewing companies highlighted in the 248 high quality undervalued stocks.
- Strengthen your watchlist with businesses filtered through the solid balance sheet and fundamentals stocks screener (415 results).
- Get ahead of the crowd by scanning the screener containing 548 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com